ONC vs. VRTX: BeOne Medicines vs. Vertex Pharmaceuticals Stock Comparison
How do BeOne Medicines (ONC) and Vertex Pharmaceuticals (VRTX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BeOne Medicines (ONC) and Vertex Pharmaceuticals (VRTX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Vertex Pharmaceuticals (VRTX) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | ONC | VRTX |
|---|---|---|
| Name | BeOne Medicines Ltd. American Depositary Shares | Vertex Pharmaceuticals Incorporated Common Stock |
| Country/Region | Switzerland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 46.49 billion USD | 138.71 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | February 3, 2016 | July 24, 1991 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ONC | VRTX |
|---|---|---|
| Total Return (1Y) | 30.59% | 34.89% |
| Total Return (3Y, Annualized) | 30.15% | 14.44% |
| Total Return (5Y, Annualized) | 2.48% | 23.65% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ONC | VRTX |
|---|---|---|
| Volatility (1Y, Annualized) | 35.90% | 29.73% |
| Beta (5Y) | 0.59 | 0.29 |
| Max Drawdown (5Y) | -68.89% | -29.07% |
| Avg. Volume (3M) | 405.29K | 1.25M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ONC | VRTX |
|---|---|---|
| Sharpe Ratio (1Y) | 0.73 | 1.03 |
| Sortino Ratio (1Y) | 1.15 | 1.68 |
Profitability
ROE (TTM)
Both BeOne Medicines (ONC) at 18.40% and Vertex Pharmaceuticals (VRTX) at 20.80% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.40%
- Max
- 109.18%
- ONC
- 18.40%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.80%
- Max
- 109.18%
- VRTX
- 20.80%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Vertex Pharmaceuticals (VRTX) at 30.70% keeps the most of each sales dollar — above its industry’s net margin range — and BeOne Medicines (ONC) at 13.86% also retains a top-quartile share.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.86%
- Max
- 18.05%
- ONC
- 13.86%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.70%
- VRTX
- 30.70%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both BeOne Medicines (ONC) at 22.15% and Vertex Pharmaceuticals (VRTX) at 35.57% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.15%
- Max
- 83.12%
- ONC
- 22.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.57%
- Max
- 83.12%
- VRTX
- 35.57%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ONC | VRTX |
|---|---|---|
| ROE (TTM) | 18.40% | 20.80% |
| ROA (TTM) | 8.42% | 10.62% |
| Net Margin (TTM) | 13.86% | 30.70% |
| Operating Margin (TTM) | 22.15% | 35.57% |
| Gross Margin (TTM) | 89.39% | 54.81% |
Growth
Revenue Growth
Both BeOne Medicines (ONC) at 40.23% and Vertex Pharmaceuticals (VRTX) at 8.90% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Neither BeOne Medicines (ONC) nor Vertex Pharmaceuticals (VRTX) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | ONC | VRTX |
|---|---|---|
| Revenue Growth (YoY) | 40.23% | 8.90% |
| Revenue Growth (3Y CAGR) | 55.69% | 10.35% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | 6.12% |
Financial Strength
Current Ratio (MRQ)
BeOne Medicines (ONC) at 3.55 keeps current ratio within its industry’s typical mid-range, while Vertex Pharmaceuticals (VRTX) at 2.34 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for VRTX.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ONC
- 3.55
- Q1
- 2.47
- Min
- 0.10
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.34
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- VRTX
- 2.34
- Min
- 0.10
Debt / Equity (MRQ)
Both BeOne Medicines (ONC) at 0.35 and Vertex Pharmaceuticals (VRTX) at 0.31 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.35
- Max
- 1.42
- Q3
- 0.65
- ONC
- 0.35
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.31
- Max
- 1.42
- Q3
- 0.65
- VRTX
- 0.31
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ONC | VRTX |
|---|---|---|
| Current Ratio (MRQ) | 3.55 | 2.34 |
| Debt / Equity (MRQ) | 0.35 | 0.31 |
| Net Debt / EBITDA | -2.80 | 0.03 |
Dividends
Dividend Yield (TTM)
Neither BeOne Medicines (ONC) nor Vertex Pharmaceuticals (VRTX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- VRTX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither BeOne Medicines (ONC) nor Vertex Pharmaceuticals (VRTX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- VRTX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ONC | VRTX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Vertex Pharmaceuticals (VRTX) at 35.21 is near its industry’s usual P/E ratio, while BeOne Medicines (ONC) at 52.17 sits in the richer quartile — ONC needs stronger growth or earnings quality to justify the premium.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.17
- Max
- 85.34
- ONC
- 52.17
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.21
- Max
- 85.34
- Q3
- 43.46
- VRTX
- 35.21
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both BeOne Medicines (ONC) at 7.04 and Vertex Pharmaceuticals (VRTX) at 10.71 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.04
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ONC
- 7.04
- Q1
- 3.01
- Min
- 0.01
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.71
- Max
- 58.18
- Q3
- 25.77
- VRTX
- 10.71
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both BeOne Medicines (ONC) at 7.98 and Vertex Pharmaceuticals (VRTX) at 6.63 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.98
- Max
- 13.53
- ONC
- 7.98
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
VRTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.63
- Max
- 13.53
- VRTX
- 6.63
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ONC | VRTX |
|---|---|---|
| P/E Ratio (TTM) | 52.17 | 35.21 |
| P/S Ratio (TTM) | 7.04 | 10.71 |
| P/B Ratio (MRQ) | 7.98 | 6.63 |
| Free Cash Flow Yield (TTM) | 2.21% | 1.69% |